Applied Genetic Technologies Corp   Report issue

For profit Phase 2 Phase 3
Founded: Alachua Florida United States (1999)

Organization Overview

First Clinical Trial
1999
NCT00002811
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Applied Genetics | Applied Genetics Technologies Corporation | Applied Genetic Technologies Corp | Applied Genetic Technologies Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

alpha 1-Antitrypsin Deficiency (Phase 2)

Blindness (Phase 2)

Color Vision Defects (Phase 2)

Ichthyosis (Phase 3)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Leber Congenital Amaurosis (Phase 2)

Precancerous Conditions (Phase 3)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Retinoschisis (Phase 2)

Xeroderma Pigmentosum (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 8